Vanda Pharmaceuticals VNDA Insider Ownership

NASDAQ VNDA

$4.17 +0.08 (+1.96%)

At close: Oct 20, 2026 · 4:00 PM EDT

Insider Holdings by Owner

5.39Mn Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

8.80%

■0% pp QoQ

Shares Held by Insiders

5.32Mn

filed for Sep 2026

■0.00% QoQ

Shares Outstanding

60.45Mn

60,454,687 shares

Direct Holdings

5.32Mn

Indirect: 0

Net Shares Traded (QoQ)

no net change in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 10, 2026

Over the past year, VNDA insiders sold $2.82 million of stock (344.34K shares) on the open market and bought none.

By number of insiders, Vanda Pharmaceuticals saw 6 insiders sell on the open market over the past 12 months and none buy.
Mihael Hristos Polymeropoulos (President and CEO) led open-market sales of Vanda Pharmaceuticals stock over the past 12 months with $1.28 million (156.24K shares), most recently on March 2, 2026.
Away from the open market, VNDA insiders received 828.7K shares in stock awards and gave away 25.84K shares as gifts over the last 12 months.
Business Quant data shows Vanda Pharmaceuticals insiders holding 5.32Mn shares in total in their latest Form 4 filings, unchanged from 5.32Mn shares at the end of Q2 2026.
Vanda Pharmaceuticals insiders report no indirect holdings: all 5.32Mn shares are held directly.
VNDA's insider total is spread across 12 insiders who have filed a Form 4 in the past two years.
Vanda Pharmaceuticals' three biggest insider holders are Mihael Hristos Polymeropoulos (President and CEO, 2.7Mn shares), Gunther Birznieks (SVP, Business Development, 494.2K shares) and Kevin Patrick Moran (SVP, CFO & Treasurer, 411.38K shares), based on their latest Form 4 filings.
Mihael Hristos Polymeropoulos alone accounts for 50.81% of the shares held by Vanda Pharmaceuticals insiders.
Institutions accounted for 82.04% of VNDA's outstanding shares in Q2 2026, insiders about 8.80% per their latest Form 4 filings, and other investors, including the public, about 9.16%.
In the past year, 12 insiders of Vanda Pharmaceuticals submitted 20 Form 4 filings reporting trades, awards or other transactions.
The insider holdings and trades above for Vanda Pharmaceuticals reflect Form 4 filings through June 8, 2026.

Form 4 Holdings

Insiders Holding VNDA

Insiders 13

Shares held 5.39Mn

Of outstanding 8.91%

#	Insider	Position	Direct	Total	Share of Insiders	Last Filed
1	Mihael Hristos Polymeropoulos	President And Ceo	2,704,496	2,704,496	50.2%	04 Mar, 2026
2	Gunther Birznieks	Svp, Business Development	494,197	494,197	9.2%	04 Mar, 2026
3	Kevin Patrick Moran	Svp, Cfo Treasurer	411,380	411,380	7.6%	04 Mar, 2026
4	Timothy Williams	Svp General Counsel	377,450	377,450	7.0%	04 Mar, 2026
5	Joakim Wijkstrom	Svp, Chief Marketing Officer	333,469	333,469	6.2%	04 Mar, 2026
6	Richard W Dugan	Director	219,054	219,054	4.1%	08 Jun, 2026
7	Phaedra Chrousos	Director	164,950	164,950	3.1%	08 Jun, 2026
8	Anne Sempowski Ward	Director	160,667	160,667	3.0%	08 Jun, 2026
9	Tage Honore	Director	135,069	135,069	2.5%	08 Jun, 2026
10	Stephen Ray Mitchell	Director	112,846	112,846	2.1%	08 Jun, 2026
11	Daniel Patrick Mcguire	Svp, Gc And Secretary	109,982	109,982	2.0%	08 Jun, 2026
12	Charles Cliff Duncan	Director	98,701	98,701	1.8%	08 Jun, 2026
13	Thomas Watkins	Director	63,064	63,064	1.2%	03 Jun, 2022

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

1,085 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
04 Jun, 2026	Daniel Patrick Mcguire	Svp, Gc And Secretary	Acquired A	80,000	$0.00	$0	109,982	Direct
04 Jun, 2026	Phaedra Chrousos	Director	Acquired A	41,600	$0.00	$0	164,950	Direct
04 Jun, 2026	Anne Sempowski Ward	Director	Acquired A	41,600	$0.00	$0	160,667	Direct
04 Jun, 2026	Stephen Ray Mitchell	Director	Acquired A	41,600	$0.00	$0	112,846	Direct
04 Jun, 2026	Richard W Dugan	Director	Acquired A	41,600	$0.00	$0	219,054	Direct
04 Jun, 2026	Tage Honore	Director	Acquired A	41,600	$0.00	$0	135,069	Direct
04 Jun, 2026	Charles Cliff Duncan	Director	Acquired A	41,600	$0.00	$0	98,701	Direct
18 May, 2026	Stephen Ray Mitchell	Director	Disposed G	25,836	$0.00	$0	71,246	Direct
22 Apr, 2026	Charles Cliff Duncan	Director	Acquired A	57,101	$0.00	$0	57,101	Direct
02 Mar, 2026	Mihael Hristos Polymeropoulos	President And Ceo	Disposed S	156,235	$8.17	$1.28Mn	2,704,496	Direct
02 Mar, 2026	Gunther Birznieks	Svp, Business Development	Disposed S	42,431	$8.27	$350.73K	494,197	Direct
02 Mar, 2026	Timothy Williams	Svp General Counsel	Disposed S	42,434	$8.27	$350.76K	377,450	Direct
02 Mar, 2026	Joakim Wijkstrom	Svp, Chief Marketing Officer	Disposed S	30,800	$8.27	$254.59K	333,469	Direct
02 Mar, 2026	Kevin Patrick Moran	Svp, Cfo Treasurer	Disposed S	42,442	$8.27	$350.82K	411,380	Direct
23 Feb, 2026	Tage Honore	Director	Disposed S	30,000	$8.03	$240.90K	93,469	Direct
18 Feb, 2026	Kevin Patrick Moran	Svp, Cfo Treasurer	Acquired A	125,000	$0.00	$0	453,822	Direct
18 Feb, 2026	Gunther Birznieks	Svp, Business Development	Acquired A	125,000	$0.00	$0	536,628	Direct
18 Feb, 2026	Mihael Hristos Polymeropoulos	President And Ceo	Acquired A	525,000	$0.00	$0	2,860,731	Direct
18 Feb, 2026	Joakim Wijkstrom	Svp, Chief Marketing Officer	Acquired A	125,000	$0.00	$0	364,269	Direct
18 Feb, 2026	Timothy Williams	Svp General Counsel	Acquired A	125,000	$0.00	$0	419,884	Direct

Showing 1 to 20 of 1,085 transactions